Background. Concern for serious infection due to β-lactam-resistant viridans group streptococci (VGS) is a major factor driving empiric use of an anti-gram-positive antimicrobial in patients with febrile neutropenia. We sought to develop and validate a prediction model for the presence of β-lactam resistance in VGS causing bloodstream infection (BSI) in neutropenic patients.
Febrile neutropenia is a common, life-threatening condition for cancer patients [1] . It is well accepted that neutropenic patients with suspected infection require empiric antimicrobials with efficacy against gramnegative bacteria [1] . However, the need for the empiric use of antimicrobials with specific activity against grampositive bacteria has long been debated [2] [3] [4] [5] [6] . A metaanalysis of randomized trials mainly conducted in the 1980s found no mortality benefit in the empiric addition of an anti-gram-positive agent to febrile neutropenic patients but did find that the use of such agents resulted in fewer gram-positive superinfections [3] . A major reason for considering an additional anti-gram-positive antimicrobial in the treatment of patients with febrile neutropenia is the concern for severe viridans group streptococcal (VGS) infection [7] [8] [9] [10] [11] . Life-threatening VGS infections are sufficiently common in neutropenic patients that some clinical centers use prophylactic vancomycin in high-risk patients [12, 13] . Given the significant negative impact of the broad use of anti-gram-positive antimicrobials, such as the emergence of vancomycin-resistant enterococci, better targeting of their use is needed [14] [15] [16] .
Two main pieces of data support the idea that VGS bloodstream infections (BSIs) in neutropenic patients respond better when vancomycin is part of the initial regimen. The first is a randomized trial of pediatric patients in which vancomycin or placebo was added to a backbone regimen of ticarcillin-clavulanate and amikacin [4] . In that study, the placebo group had higher rates of breakthrough bacteremia with gram-positive organisms, including a single lethal VGS infection. The second is an analysis of 10 randomized trials of febrile neutropenic patients conducted between 1980 and 1993, which found a significantly lower mortality rate for patients with VGS BSI who received vancomycin as part of their initial antimicrobial regimen [6] . Together, these data resulted in several iterations of the Infectious Diseases Society of America (IDSA) neutropenia guidelines recommending consideration of empiric vancomycin use in patients with possible VGS infection [17] [18] [19] . Importantly, in both of the previously noted studies, the initial β-lactam used had limited anti-VGS activity [4, 6, 20] . However, over the last 15 years the empiric therapy of febrile neutropenic patients has changed to β-lactam agents with increased anti-VGS activity, such as piperacillin-tazobactam, cefepime, and carbapenems [1, 21] .
The 2010 IDSA neutropenia guidelines recognize that β-lactam antibiotics currently employed as empiric monotherapy in febrile neutropenia generally have good in vitro anti-VGS activity, and thus the guidelines do not routinely recommend using vancomycin when VGS infection is suspected [1] . However, the extent to which clinicians will follow this revised recommendation is unknown given the paucity of current data in this regard [22] . Moreover, although VGS resistance to β-lactams is well described, there is a dearth of recent information regarding VGS susceptibility to agents now used empirically in febrile neutropenia [23, 24] . Thus, we sought to determine whether the presence of VGS bloodstream isolates resistant to β-lactam agents commonly used in the empiric treatment of neutropenic fever could be predicted clinically to facilitate better targeting of antigram-positive antimicrobials.
METHODS

Setting, Patients, and Definitions
Detailed methods are available in the Supplementary Data. A VGS BSI was defined in accordance with Centers for Disease Control and Prevention guidelines (available at: http://www. cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf ). Neutropenia was defined as an absolute neutrophil count <500 cells/µL. The study was performed in 2 stages at the MD Anderson Cancer Center in Houston, Texas. First, we retrospectively analyzed data from unique neutropenic patients with a monomicrobial VGS BSI between 1 January 2000 and 31 December 2010. These patients were classified as the derivation cohort. In the second stage, we prospectively collected all VGS BSI-causing isolates in neutropenic patients between 1 January 2011 and 31 March 2013 and analyzed patient data as for the retrospective cohort. These patients were classified as the validation cohort. Clinical and microbiologic data were abstracted from the comprehensive electronic medical record. Measurement of compliance with the IDSA guidelines regarding empiric use of antigram-positive antibiotics is detailed in the Supplementary Data [1] . The VGS shock syndrome was defined using the accepted definition for septic shock [25] or by the development of otherwise unexplained adult respiratory distress syndrome (ARDS) [8] . Anti-gram-positive antimicrobials were defined as vancomycin, daptomycin, and linezolid. Nosocomial onset was defined as onset of signs and symptoms of infection after >48 hours of hospitalization. The MD Anderson Cancer Center Institutional Review Board approved the study with a waiver of informed consent.
Microbiologic Methods and Antimicrobial Susceptibility
Bacterial isolates were identified as VGS using standard microbiologic methods [26] . Minimum inhibitory concentrations (MICs) for VGS isolates were routinely determined by the clinical microbiology laboratory for penicillin, ceftriaxone, and fluoroquinolones using Etest (bioMérieux, Durham, North Carolina) and interpreted according to the 2010 Clinical and Laboratory Standards Institute (CLSI) guidelines for VGS [27] , except that fluoroquinolone susceptibility testing was not done during 2007-2010. As part of this study, additional Etests were performed on VGS isolates with a penicillin MIC of ≥1 µg/mL collected during 2011-2013 to determine the MICs of cefepime, meropenem, and piperacillin-tazobactam. VGS organisms from the 2000-2010 cohort were not available for the additional antimicrobial testing.
Clinical Care
During the study period, patients with neutropenic fever were treated according to standard algorithms. Antimicrobial monotherapy mainly consisted of either piperacillin-tazobactam, cefepime, imipenem-cilastatin, or meropenem. Consideration of adding an anti-gram-positive antimicrobial was recommended for patients who were receiving fluoroquinolone prophylaxis, had a suspected catheter-related or soft tissue infection, or had septic shock upon presentation in accordance with the 1997 and 2002 IDSA neutropenia guidelines [18, 19] .
Statistical Analysis
The primary outcome was the occurrence of β-lactam resistance among VGS causing BSI, defined as an organism with a penicillin MIC ≥2 µg/mL. The rationale for choosing this breakpoint is elucidated in the Results section. Characteristics of patients in the derivation cohort having an association with a BSI due to a VGS organism with penicillin MIC of ≥2 µg/mL were determined using Fisher exact test for dichotomous variables and Student t test for continuous variables. Binary logistic regressions evaluated associations between baseline patient characteristics and having a VGS organism with a penicillin MIC of ≥2 µg/mL using data from the derivation cohort. The regression models developed on the derivation sample were then used to predict having a VGS organism with a penicillin MIC of ≥2 µg/mL in the validation cohort. Area under the curve for the derivation and validation samples were compared using the method of DeLong et al [28] . All tests of significance were 2-sided, and statistical significance was defined at P ≤ .05. Statistical analysis was performed using SPSS Statistics version 19 (IBM, Armonk, New York) and Stata version 12.1 (StataCorp, College Station, Texas).
RESULTS
Patient Characteristics
During the period 2000-2010 (derivation cohort), 569 unique VGS BSIs occurred in neutropenic patients. From 2011 to March 2013 (validation cohort), there were 163 qualifying cases. Clinical characteristics of the 732 neutropenic patients with VGS BSI are shown in Table 1 . Nearly all cases occurred in patients with hematologic malignancies and severe neutropenia (neutrophils <100/µL), and there was no significant difference in underlying diseases between the 2 cohorts (Table 1) . There were high rates of empiric use of an anti-gram-positive antimicrobial in both groups, although the rate of empiric use of such agents was significantly higher in the 2011-2013 cohort ( Table 1) . The MIC at which 50% of the isolates were inhibited (MIC 50 ) for penicillin did not significantly change over the course of the study ( penicillin MIC 50 for entire cohort = 0.19).
In Vitro Susceptibility of VGS Isolates to β-Lactam Agents
Next, we sought to find a penicillin MIC breakpoint at which β-lactams commonly used in the treatment of febrile neutropenia, including cefepime, meropenem, and piperacillin-tazobactam, would be expected to be successful in treatment of the VGS BSI. We only studied VGS isolates with a penicillin MIC of ≥1 µg/mL because all VGS strains with a penicillin MIC of 1 µg/mL were fully susceptible to all tested agents ( Figure 1 ). VGS isolates with a penicillin MIC of 2 were generally susceptible to the tested β-lactams, with the exception of meropenem ( Figure 1 ). VGS isolates considered penicillin resistant by CLSI guidelines (MIC ≥4 µg/mL) were generally nonsusceptible to the tested agents with the exception of piperacillin-tazobactam ( Figure 1) . Thus, VGS BSI isolates with in vitro nonsusceptibility 127 (22) 33 (20) .67
In shock/ARDS at presentation 42 (7) 20 (12) .06
VGS shock syndrome 54 (9) 22 (14 to cefepime, meropenem, and piperacillin-tazobactam were restricted to strains with a penicillin MIC of ≥2 µg/mL.
Identification of Clinical Factors Associated With β-LactamNonsusceptible VGS
We next attempted to identify baseline patient risk factors indicating an increased likelihood of being infected with VGS resistant to β-lactam antimicrobials commonly used in the treatment of febrile neutropenia. In light of our in vitro data, we used a penicillin MIC cutoff of ≥2 µg/mL for labeling an isolate as β-lactam-nonsusceptible, with the understanding that such isolates are not fully resistant to all β-lactam agents. For our derivation cohort, out of 569 cases, we identified 99 infections (17%; 95% confidence interval [CI], 14%-21%) due to β-lactam-nonsusceptible VGS (Table 2) . By multivariate analysis, 3 risk factors were significantly associated with the presence of β-lactam-nonsusceptible VGS: nosocomial onset of infection, use of a β-lactam agent as antimicrobial prophylaxis, and receipt of a β-lactam agent as a therapeutic agent in the previous 30 days (Table 2 ). When only these 3 variables were included in the logistic regression model, there was no significant difference in the association with VGS β-lactam nonsusceptibility compared with when all baseline categorical variables (listed in Table 2 ) were included (P = .20; Figure 2A ). The rate of β-lactam-nonsusceptible VGS did not significantly differ (P = .82) in the validation cohort (30/163 [18%]; 95% CI, 12%-24%) from the derivation cohort (99/569 [17%]; 95% CI, 14%-21%). Similarly, the 3 variables identified in the derivation were also associated with the presence of β-lactamresistant VGS in the validation cohort (Supplementary Tables 1  and 2 ). When all dichotomous variables listed in Table 2 were considered, the model generated using our derivation cohort performed equally well on patients in our validation cohort (P = .56; Figure 2B ). Similar to our derivation cohort, in the validation cohort the model generated by the 3 significant variables identified using the derivation cohort data was not significantly different compared with the model generated using all dichotomous variables (P = .73; Figure 2C ). Finally, there was no significance difference when using the model including the 3 significant variables alone generated on the derivation cohort between patients in the derivation or validation cohort (P = .81; Figure 2D ).
Characterization of Various Combinations of Variables Associated With Presence of β-Lactam-Nonsusceptible VGS
Having determined the 3 variables that were most significantly associated with the development of β-lactam-nonsusceptible VGS infection, we next sought to determine how these variables might best be utilized in a clinically applicable manner. Because of the potential life-threatening consequences of not starting an anti-gram-positive agent in a febrile neutropenic patient with a β-lactam-nonsusceptible VGS BSI, we aimed to find a combination of variables with a high negative predictive value. For the derivation and validation cohorts, the absence of all 3 risk factors associated with β-lactam-nonsusceptible VGS had a negative predictive value of at least 0.98 (Table 3 ). For the entire study, only 3 of 338 patients (1%; 95% CI, 0%-3%) who lacked all 3 risk factors were infected with a VGS organism with a penicillin MIC of ≥2 µg/mL. When a cutoff of at least 2 risk factors was considered, the specificity and positive predictive value significantly improved, but the negative predictive value decreased (Table 3) . For the entire cohort, only 4 patients had all 3 risk factors. Thus, we conclude that the presence of 1 or more of the 3 identified risk factors would be most clinically useful for identifying neutropenic patients at risk of VGS nonsusceptible to β-lactams.
Potential Impact of β-Lactam-Nonsusceptible Prediction Rule on Use of Anti-Gram-Positive Antimicrobial Therapy
To determine how implementation of a β-lactam-nonsusceptible prediction rule might affect antibiotic utilization, we Figure 1 . Viridans group streptococci (VGS) nonsusceptibility to β-lactams commonly used in the treatment of neutropenic fever is limited to strains with a penicillin minimum inhibitory concentration (MIC) of at least 2 µg/mL. Forty-eight unique VGS isolates with a penicillin MIC of ≥1 µg/mL that had caused a bloodstream infection in a neutropenic cancer patient were tested for susceptibility to ceftriaxone, cefepime, meropenem, and piperacillin-tazobactam. Although ceftriaxone is not typically used in the empiric treatment of neutropenic fever, it is often used in the treatment of streptococcal infections and so is included here for reference purposes. The penicillin MICs of the isolates are shown on the x-axis. The number of susceptible (dotted bars) and resistant (solid bars) isolates for each of the indicated antimicrobials is shown on the y-axis with classification as per Clinical and Laboratory Standards Institute (CLSI) guidelines [27] . Susceptibility guidelines for VGS are not available for piperacillin-tazobactam, so a cutoff MIC of 16 µg/mL was chosen. *The 4 isolates with a penicillin MIC of 2 that were classified as resistant to meropenem by CLSI guidelines would have been classified as susceptible by European Committee on Antimicrobial Susceptibility Testing guidelines [29] . Abbreviations: BSI, bloodstream infection; MIC, minimum inhibitory concentration; VGS, viridans group streptococci.
examined treatment of VGS BSIs from patients in both cohorts. Empiric anti-gram-positive therapy was used in 554 of 732 (76%; 95% CI, 72%-79%) of VGS BSI cases. In contrast to a previous report [6] , we did not find a significant difference (P = .08) in 30-day attributable mortality in patients who did not receive an empiric anti-gram-positive antimicrobial (3/ 178 [2%]; 95% CI, 1%-5% for patients not receiving an empiric anti-gram-positive agent vs 27/554 [5%]; 95% CI, 3%-7% for patients receiving an empiric anti-gram-positive antimicrobial). When patients who were in shock at presentation were excluded from the analysis, again there was no significant difference (P = .30) in 30-day attributable mortality between patients who did or did not receive an anti-gram-positive agent (1/174 [1%]; 95% CI, 0%-4% for patients not receiving an empiric anti-gram-positive agent vs 10/496 [2%]; 95% CI, 1%-4% for patients receiving an empiric anti-gram-positive antimicrobial). Of the 554 empiric uses of anti-gram-positive therapy, 235 patients lacked all 3 risk factors for β-lactam-nonsusceptible VGS (42%; 95% CI, 38%-47%), and thus would have met our criteria for withholding empiric anti-gram-positive antimicrobial therapy. For the entire cohort, 338 of 732 patients (46%; 95% CI, 43%-50%) lacked all 3 risk factors for β-lactam-nonsusceptible VGS. For the 2011-2013 cohort (ie, those patients treated since publication of the 2010 IDSA guidelines), 156 of 163 patients (96%; 95% CI, 91%-98%) received empiric therapy with an anti-gram-positive antimicrobial, whereas 25 of 163 patients (15%; 95% CI, 11%-22%) met the IDSA criteria for empiric use of such agents.
DISCUSSION
The concern that febrile neutropenic patients may have a VGS infection that will not respond to β-lactam antimicrobials contributes to the empiric use of anti-gram-positive agents in such patients [2, 4] . Indeed, the only data showing clinical benefit to including anti-gram-positive agents empirically for febrile neutropenic patients is derived from VGS infection [4, 6, 30] . The fact that the evidence supporting empiric anti-gram-positive use in the treatment of VGS infection was generated >20 years ago was a major impetus for the research described herein.
Our data regarding prediction of β-lactam-nonsusceptible VGS isolates suggest an approach to help reduce the widespread, empiric use of anti-gram-positive therapy in patients with febrile neutropenia. Three pieces of clinical data were independently significantly associated with the presence of β-lactam-nonsusceptible VGS: whether the patient was taking a β-lactam prophylactically, had received treatment with a β-lactam in the previous 30 days, or was hospitalized at time of VGS isolation. By combining these 3 pieces of information, we were able to develop a model that reliably excluded the presence of a VGS isolate with a penicillin MIC of ≥2 µg/mL. This cutoff point was chosen because VGS isolates with a penicillin MIC of ≤1 µg/mL universally had MICs within the susceptible range of β-lactam agents commonly used to treat neutropenic fever. When both cohorts were analyzed, application of the model would have reduced empiric anti-gram-positive therapy by 42%. The near universal use of anti-gram-positive antimicrobials in our 2011-2013 cohort occurred even though such patients rarely met the 2010 IDSA criteria for use of such agents, which speaks to the urgent need to improve targeting of anti-gram-positive antimicrobials. Limited data from the 1980s and 1990s have raised concerns that β-lactam therapy may be suboptimal for serious VGS BSI [4, 6] . In contrast to previous data, we did not observe any significant benefit to the empiric addition of an anti-gram-positive agent to neutropenic patients with VGS BSI, although our ability to detect such an effect was limited because of the high rates of empiric anti-gram-positive antimicrobial use, particularly in patients who presented with shock. However, we were able to find 174 patients with VGS BSI who did not receive empiric therapy with an anti-gram-positive agent, and only 1 of these patients who was not in shock at presentation progressed to develop the VGS shock syndrome and died. Compared to ceftazidime, which was prominently utilized in the 1990s, the β-lactam agents currently used for empiric treatment of neutropenic fever have much improved anti-VGS activity in vitro [20, 21, 31] . Indeed, nearly all VGS isolates with elevated penicillin MICs were readily inhibited in vitro by such agents as cefepime and piperacillin-tazobactam (Figure 1) . Thus, the efficacy of β-lactam agents in our cohort may be due to their inherent anti-VGS activity. Given that we found no evidence of increasing rates of β-lactam resistance among VGS BSI isolates, it is likely that the anti-VGS efficacy of currently recommended β-lactam antimicrobials will be maintained in the coming years.
There are some limitations of our study that bear mentioning. First, given that the data were derived from a single center, it is not clear how well our prediction rule would function in other settings. However, the 18% rate of VGS with a penicillin MIC of ≥2 µg/mL observed in our study is quite similar to the 17% reported from British Columbia, Canada [20] , and the 22% from Spain [32] . Similarly, given that this was not a randomized trial, we cannot definitively state that β-lactam monotherapy was equivalent to anti-gram-positive therapy for VGS BSI. However, randomized trials of antimicrobial use of neutropenic fever are becoming increasingly rare, and there is a very low likelihood that such a trial could enroll a sufficient number of VGS patients to definitively address the relative efficacy of different Figure 2 . Receiver operating curves comparing the results of various logistic regression analyses. All the logistic regression models were developed on the derivation cohort data. A, Data from the derivation cohort using all baseline dichotomous variables (blue line) compared with using only 3 variables found to be significant by multivariate analysis (ie, nosocomial onset of infection, receipt of a β-lactam as prophylaxis, and receipt of a β-lactam for therapeutic purposes within 30 days of disease onset; red line). B, Data from both cohorts using all dichotomous variables in the analysis. C, Data from the validation cohort using all baseline dichotomous variables (blue line) compared with using only the 3 variables found to be significant by multivariate analysis in the derivation. D, Comparison of using only the 3 significant variables in the derivation and validation cohorts. For all panels, the green line is shown as reference. Abbreviation: AUC, area under the curve.
antimicrobial regimens for VGS infection. Also, we attempted to minimize data collection issues inherent in the observational nature of the study by relying on the electronic medical record and using a standardized data collection method. Finally, to clarify the impact of VGS BSI on patient outcomes, we excluded cases of polymicrobial infection, which make up a significant proportion of patients with VGS infection, and thus we cannot definitively extrapolate our data to polymicrobial infections involving VGS.
In summary, these data represent by far the largest analysis of VGS BSI in cancer patients with neutropenia. We have identified that significant opportunities exist for improving antibiotic administration for VGS BSI, both from an empiric and a definitive treatment standpoint, and have found that straightforward clinical criteria can be used to determine the risk of β-lactamresistant VGS.
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